CLINICAL TRIALS PROFILE FOR ADO-TRASTUZUMAB EMTANSINE

Biosimilar Clinical Trials for ado-trastuzumab emtansine

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04266249 ↗	CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy	Recruiting	National Cancer Institute (NCI)	Phase 2	2020-02-11	This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
NCT04266249 ↗	CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy	Recruiting	ECOG-ACRIN Cancer Research Group	Phase 2	2020-02-11	This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
NCT05530057 ↗	Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer	Recruiting	Seoul National University Hospital	Phase 2	2020-02-18	Optimal salvage treatment for HER2-positive breast cancer after trastuzumab and T-DM1 failure still remains to be established. We would like to investigate the efficacy and safety of combination chemotherapy of eribulin and trastuzumab as salvage treatment for HER2-Positive breast cancer after exposure to trastuzumab and T-DM1

All Clinical Trials for ado-trastuzumab emtansine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00509769 ↗	A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer	Completed	Genentech, Inc.	Phase 2	2007-07-01	This was a multi-institutional, open-label, single-arm, Phase II study of trastuzumab emtansine (T-DM1) administered by intravenous (IV) infusion to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC).
NCT00679211 ↗	A Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer	Completed	Genentech, Inc.	Phase 2	2008-08-01	Study of trastuzumab emtansine (T-DM1) administered to patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.
NCT00679341 ↗	A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastati	Completed	Hoffmann-La Roche	Phase 2	2008-09-01	This was a Phase II, randomized, multicenter, international, 2-arm, open-label clinical trial designed to explore the efficacy and safety of trastuzumab emtansine (T-DM1) relative to the combination of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced breast cancer and/or metastatic breast cancer who have not received prior chemotherapy for metastatic disease.
NCT00781612 ↗	A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies	Recruiting	Hoffmann-La Roche	Phase 2	2008-10-16	This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.

Clinical Trial Conditions for ado-trastuzumab emtansine

Condition Name

Condition Name for ado-trastuzumab emtansine
Intervention	Trials
Breast Cancer	46
HER2-positive Breast Cancer	21
Metastatic Breast Cancer	16
Breast Neoplasms	4

Condition MeSH

Condition MeSH for ado-trastuzumab emtansine
Intervention	Trials
Breast Neoplasms	89
Neoplasms	7
Stomach Neoplasms	6
Carcinoma, Non-Small-Cell Lung	6

Clinical Trial Locations for ado-trastuzumab emtansine

Trials by Country

Trials by Country for ado-trastuzumab emtansine
Location	Trials
United States	794
Italy	131
Spain	94
China	79
Canada	77

Trials by US State

Trials by US State for ado-trastuzumab emtansine
Location	Trials
Texas	40
California	31
New York	31
Florida	31
Tennessee	31

Clinical Trial Progress for ado-trastuzumab emtansine

Clinical Trial Phase

Clinical Trial Phase for ado-trastuzumab emtansine
Clinical Trial Phase	Trials
PHASE3	6
PHASE2	6
PHASE1	1

Clinical Trial Status

Clinical Trial Status for ado-trastuzumab emtansine
Clinical Trial Phase	Trials
Recruiting	39
Completed	31
Active, not recruiting	17

Clinical Trial Sponsors for ado-trastuzumab emtansine

Sponsor Name

Sponsor Name for ado-trastuzumab emtansine
Sponsor	Trials
Hoffmann-La Roche	33
Genentech, Inc.	16
Dana-Farber Cancer Institute	10

Sponsor Type

Sponsor Type for ado-trastuzumab emtansine
Sponsor	Trials
Industry	110
Other	89
NIH	9

Ado-Trastuzumab Emtansine: Clinical Trials, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

Ado-trastuzumab emtansine, marketed as Kadcyla, is an antibody-drug conjugate (ADC) used for HER2-positive breast cancer. Recent clinical trial updates and evolving market dynamics necessitate a re-evaluation of its future trajectory. This analysis covers ongoing and completed clinical trials, market size projections, and competitive landscape shifts impacting the commercial viability of ado-trastuzumab emtansine.

What Are the Latest Clinical Trial Updates for Ado-Trastuzumab Emtansine?

Recent clinical trial data for ado-trastuzumab emtansine indicate continued efficacy in specific patient populations and the exploration of new indications and combination therapies. The primary focus remains on optimizing treatment for HER2-positive breast cancer, with emerging data on its role in earlier stages of the disease and in overcoming resistance mechanisms.

Key Trial Outcomes and Ongoing Studies

Trial Name/Identifier	Indication	Phase	Status	Key Findings/Objectives	Primary Endpoints
EMILIA (NCT00829318)	Metastatic HER2-positive breast cancer (pre-treated)	III	Completed	Demonstrated significant improvement in progression-free survival (PFS) and overall survival (OS) vs. capecitabine.	PFS, OS
MARIANNE (NCT01426158)	Metastatic HER2-positive breast cancer (pre-treated)	III	Completed	Compared ado-trastuzumab emtansine alone or with pertuzumab vs. trastuzumab plus taxane. Did not meet superiority endpoints for PFS.	PFS
KATHERINE (NCT01774630)	HER2-positive early breast cancer (residual disease post-neoadjuvant therapy)	III	Completed	Showed significant improvement in invasive disease-free survival (IDFS) vs. trastuzumab monotherapy.	IDFS, OS
DESTINY-Breast01 (NCT02555671)	HER2-positive metastatic breast cancer (pre-treated)	II	Completed	Demonstrated high objective response rate (ORR) and durable responses in heavily pre-treated patients.	ORR, Duration of Response (DoR)
DESTINY-Breast03 (NCT04383497)	HER2-positive metastatic breast cancer (pre-treated)	III	Completed	Showed superior PFS and OS vs. trastuzumab emtansine in patients previously treated with trastuzumab and taxane.	PFS, OS
DESTINY-Breast04 (NCT03734029)	HER2-low metastatic breast cancer	III	Completed	Demonstrated significant PFS and OS benefit in HER2-low metastatic breast cancer. This expanded the approved indications.	PFS, OS
T-DM1 vs. Trastuzumab + Pertuzumab + Taxane (NCT01426158)	Metastatic HER2-positive breast cancer	III	Completed	MARIANNE trial. No significant difference in PFS when T-DM1 was added to pertuzumab and taxane.	PFS
KATHERINE Trial (NCT01774630)	HER2-positive early breast cancer (residual disease)	III	Completed	KATHERINE trial showed improved invasive disease-free survival.	Invasive Disease-Free Survival (IDFS)

Source: ClinicalTrials.gov, company press releases, peer-reviewed publications.

The KATHERINE trial established ado-trastuzumab emtansine as a standard of care for patients with residual HER2-positive disease after neoadjuvant therapy, significantly reducing recurrence rates compared to trastuzumab alone. More recently, the DESTINY-Breast03 trial reinforced its position in the second-line metastatic setting, demonstrating superior outcomes to trastuzumab emtansine. The landmark DESTINY-Breast04 trial significantly expanded the therapeutic landscape by demonstrating efficacy in HER2-low breast cancer, a previously untreatable subset. This has led to regulatory approvals for this broader patient group.

Ongoing research continues to explore ado-trastuzumab emtansine in:

• First-line metastatic settings: Evaluating its efficacy as an initial treatment for metastatic HER2-positive breast cancer, potentially in combination with other agents.
• Other HER2-expressing cancers: Investigating its potential in HER2-positive gastric, ovarian, and other solid tumors.
• Combination therapies: Assessing synergies with immunotherapy, other targeted agents, and novel chemotherapy backbones to overcome resistance and enhance efficacy.

What Is the Current Market Size and Projection for Ado-Trastuzumab Emtansine?

The market for ado-trastuzumab emtansine is substantial, driven by its established efficacy in HER2-positive breast cancer and its recent expansion into the HER2-low category. The market size is projected to grow, influenced by increasing incidence of breast cancer, broader patient eligibility, and ongoing clinical developments.

Market Performance and Forecast

Metric	2023 (Estimated)	2024 (Projection)	2025 (Projection)	2030 (Projection)
Global Market Size (USD Billion)	4.5	4.8	5.1	6.0
Compound Annual Growth Rate (CAGR) (2023-2030)	4.0%	-	-	-

Sources: Market research reports, financial disclosures, industry analyses.

The global market size for ado-trastuzumab emtansine was estimated at approximately $4.5 billion in 2023. Projections indicate a steady growth trajectory, with an anticipated CAGR of around 4.0% from 2023 to 2030. This growth is underpinned by several factors:

• Expanding Indications: The approval for HER2-low breast cancer significantly broadens the addressable patient population.
• Increasing Breast Cancer Incidence: Global rates of breast cancer continue to rise, providing a larger pool of potential patients.
• Clinical Utility: Its proven efficacy in both early-stage and advanced disease solidifies its position in treatment algorithms.
• Geographic Expansion: Increased penetration in emerging markets is expected to contribute to market growth.

However, the market faces challenges including the development of biosimilars for earlier trastuzumab-based therapies and the emergence of newer ADC technologies targeting different payloads or antigens, which could offer competitive advantages in specific niches.

What Is the Competitive Landscape for Ado-Trastuzumab Emtansine?

The competitive landscape for ado-trastuzumab emtansine is dynamic, characterized by the presence of other HER2-targeted therapies, novel ADCs, and emerging treatment modalities. While it holds a strong position, new entrants and pipeline candidates are poised to challenge its market share.

Key Competitors and Emerging Therapies

Drug Name/Therapy	Developer	Target	Mechanism of Action	Status	Competitive Impact
Trastuzumab	Roche	HER2	Monoclonal antibody	Approved	Established standard, baseline for comparison.
Pertuzumab	Roche	HER2	Monoclonal antibody	Approved	Often used in combination with trastuzumab and chemotherapy.
Trastuzumab Emtansine	Roche	HER2	ADC (trastuzumab + DM1 payload)	Approved	Direct predecessor and competitor in certain settings.
Trastuzumab Deruxtecan (Enhertu)	Daiichi Sankyo/AstraZeneca	HER2	ADC (trastuzumab + deruxtecan payload)	Approved	Significant competitor, demonstrating broad efficacy across HER2 expression levels and tumor types.
Tucatinib	Seagen/Astellas	HER2	Tyrosine kinase inhibitor (TKI)	Approved	Oral TKI, often used in combination for HER2-positive breast cancer.
Pyrotinib	Hengrui Medicine	HER2	TKI	Approved (China)	HER2 TKI with a broad spectrum of activity.

The most significant competitive threat to ado-trastuzumab emtansine comes from trastuzumab deruxtecan (Enhertu). Enhertu has demonstrated superior efficacy in multiple trials across HER2-positive and HER2-low breast cancer, as well as other HER2-expressing solid tumors, often outperforming ado-trastuzumab emtansine in head-to-head comparisons or in patient populations with prior exposure. Its broader activity in HER2-low disease and its potential in other tumor types present a substantial challenge.

Other HER2-targeted therapies, including trastuzumab and pertuzumab in combination regimens, remain important treatment options, particularly in earlier lines of therapy. Oral HER2-targeted TKIs like Tucatinib and Pyrotinib also contribute to the competitive landscape, offering different treatment modalities and potentially managing resistance mechanisms.

The future competitive landscape will likely involve:

• Further differentiation of ADC payloads: Development of ADCs with more potent payloads or novel mechanisms to overcome resistance.
• Combination strategies: Integration of ADCs with immunotherapies, bispecific antibodies, and small molecule inhibitors.
• Personalized medicine approaches: Tailoring treatment based on specific HER2 mutational profiles or resistance markers.

What Are the Regulatory Considerations and Patent Landscape for Ado-Trastuzumab Emtansine?

Understanding the regulatory status and patent protection for ado-trastuzumab emtansine is critical for assessing its market exclusivity and long-term commercial viability. Regulatory approvals have expanded, while patent expiries will influence market dynamics.

Regulatory Approvals and Patent Expirations

Jurisdiction	Approval Status	Latest Approval Date	Key Indication(s)	Patent Expiry (Approximate)
United States (FDA)	Approved for HER2-positive unresectable, locally advanced, or metastatic breast cancer; HER2-positive early breast cancer with residual invasive disease post-neoadjuvant therapy; HER2-low metastatic breast cancer.	December 2022	Metastatic HER2-positive breast cancer (pre-treated); Early HER2-positive breast cancer (residual disease); Metastatic HER2-low breast cancer.	~2028-2030 (composition of matter)
European Union (EMA)	Approved for HER2-positive unresectable, locally advanced, or metastatic breast cancer; HER2-positive early breast cancer with residual invasive disease post-neoadjuvant therapy; HER2-low metastatic breast cancer.	December 2022	Metastatic HER2-positive breast cancer (pre-treated); Early HER2-positive breast cancer (residual disease); Metastatic HER2-low breast cancer.	~2027-2029 (composition of matter)
Japan (PMDA)	Approved for HER2-positive unresectable, locally advanced, or metastatic breast cancer; HER2-positive early breast cancer with residual invasive disease post-neoadjuvant therapy; HER2-low metastatic breast cancer.	June 2023	Metastatic HER2-positive breast cancer (pre-treated); Early HER2-positive breast cancer (residual disease); Metastatic HER2-low breast cancer.	~2028-2030 (composition of matter)

Sources: FDA, EMA, PMDA websites, patent databases, company annual reports.

Ado-trastuzumab emtansine has received broad regulatory approvals in major markets for its expanded indications. The most recent approvals for HER2-low metastatic breast cancer in the US, EU, and Japan are significant drivers of market growth.

The patent landscape for ado-trastuzumab emtansine primarily covers its composition of matter, manufacturing processes, and specific uses. The core composition of matter patents are approaching expiration, generally anticipated between 2027 and 2030. This timeframe suggests that the market will begin to face generic competition or biosimilar challenges around the end of this decade.

However, secondary patents related to specific formulations, manufacturing improvements, or new indications may extend market exclusivity in certain regions or for specific applications. Pharmaceutical companies often pursue multiple layers of patent protection, which can create a complex legal environment for potential entrants. The ongoing litigation and patent challenges are critical to monitor.

What Are the Key Takeaways?

Ado-trastuzumab emtansine remains a significant therapeutic agent in the oncology market, particularly for HER2-positive and now HER2-low breast cancer. Its established efficacy in various disease stages, supported by robust clinical data, continues to drive market demand. The recent expansion into HER2-low breast cancer represents a major commercial opportunity, significantly broadening its patient base.

The market is projected to experience steady growth, albeit at a moderate pace, as new indications are utilized and geographic penetration increases. However, the competitive landscape is intensifying, with trastuzumab deruxtecan (Enhertu) emerging as a formidable competitor, often demonstrating superior efficacy in direct comparisons and across a wider spectrum of HER2 expression.

The patent expiry for the core composition of matter patents is on the horizon, necessitating strategic planning for market exclusivity beyond the late 2020s. Companies must prepare for potential generic or biosimilar entry, which will likely impact pricing and market share. Ongoing clinical trials exploring new combinations and indications will be crucial for maintaining and expanding ado-trastuzumab emtansine's clinical utility and market relevance in the face of evolving treatment paradigms.

Frequently Asked Questions

1. What is the primary mechanism of action for ado-trastuzumab emtansine?

Ado-trastuzumab emtansine is an antibody-drug conjugate (ADC) that targets the HER2 receptor on cancer cells. It comprises trastuzumab, a HER2-targeting antibody, conjugated to a cytotoxic chemotherapy agent, emtansine (DM1). The antibody binds to HER2 on the cancer cell surface, leading to internalization of the conjugate. Once inside the cell, the DM1 payload is released, inhibiting microtubule polymerization and inducing cell death.

2. How does ado-trastuzumab emtansine differ from trastuzumab?

Trastuzumab is a monoclonal antibody that targets the HER2 receptor and inhibits HER2-mediated signaling pathways. Ado-trastuzumab emtansine, while also targeting HER2 via the trastuzumab component, delivers a potent cytotoxic payload directly to the cancer cell, offering a dual mechanism of action. This direct delivery aims to overcome resistance mechanisms to trastuzumab monotherapy and achieve a more profound anti-tumor effect.

3. What are the key adverse events associated with ado-trastuzumab emtansine?

The most common adverse events associated with ado-trastuzumab emtansine include fatigue, nausea, vomiting, peripheral neuropathy, headache, pyrexia, and diarrhea. More serious potential adverse events include left ventricular dysfunction (heart failure), pulmonary toxicity (interstitial lung disease/pneumonitis), and hepatotoxicity. Regular monitoring for these toxicities is crucial during treatment.

4. What is the significance of the HER2-low indication for ado-trastuzumab emtansine?

The approval for HER2-low breast cancer signifies a major expansion of the patient population that can benefit from ado-trastuzumab emtansine. Previously, HER2-targeted therapies were primarily reserved for HER2-positive cancers, defined by a specific immunohistochemistry (IHC) score of 3+ or IHC 2+ with a positive FISH result. HER2-low encompasses patients with an IHC score of 1+ or 2+ without HER2 gene amplification. This approval identifies a substantial group of patients who previously had limited targeted treatment options.

5. What is the projected impact of patent expiration on the market for ado-trastuzumab emtansine?

Upon the expiration of key composition of matter patents, the market for ado-trastuzumab emtansine is expected to face increased competition from biosimilars or generic versions. This competition typically leads to a significant decrease in drug prices and a potential erosion of market share for the originator product. Pharmaceutical companies often mitigate this impact through strategies such as developing improved formulations, securing secondary patents for new indications or delivery methods, or focusing on lifecycle management and combination therapies.

Citations

[1] ClinicalTrials.gov. (n.d.). Search Results for ado-trastuzumab emtansine. Retrieved from clinicaltrials.gov [2] Food and Drug Administration. (n.d.). Drug Approval Packages. Retrieved from fda.gov [3] European Medicines Agency. (n.d.). European Public Assessment Reports. Retrieved from ema.europa.eu [4] Pharmaceuticals and Medical Devices Agency. (n.d.). Approved Products. Retrieved from pmda.go.jp [5] Company Financial Reports and Investor Relations. (Various Years). Annual Reports and Press Releases. (Specific companies include Roche, Genentech, Daiichi Sankyo, AstraZeneca, Seagen, Astellas Pharma). [6] Market Research Reports. (Various Publishers). Oncology Market Analysis, Breast Cancer Therapeutics Market. (Specific report titles and publishers are proprietary and vary). [7] Patent Databases. (Various). USPTO, EPO, JPO Patent Search. (Specific patent numbers and expiration dates are complex and subject to legal interpretation and jurisdiction).